DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension
This study has been completed.
Information provided by (Responsible Party):
First received: May 24, 2006
Last updated: February 19, 2014
Last verified: February 2014
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||January 2009|
|Primary Completion Date:||January 2009 (Final data collection date for primary outcome measure)|
|Certification or Request for Extension to Delay Results Received:||January 3, 2014|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Weber MA, Black H, Bakris G, Krum H, Linas S, Weiss R, Linseman JV, Wiens BL, Warren MS, Lindholm LH. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet. 2009 Oct 24;374(9699):1423-31. doi: 10.1016/S0140-6736(09)61500-2.